
Putting patient access first; how non-industry stakeholders in the UK are tackling the challenges of developing and commercialising advanced therapies
Written by Thea Collier- Lawlor, Analyst & Josh McLuckie, Analsyt The well-known challenges faced by developers of advanced therapies for rare diseases have been under